AMAG Pharma (AMAG) Misses Q3 EPS by 16c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Join SI Premium – FREE
AMAG Pharma (NASDAQ: AMAG) reported Q3 EPS of $1.02, $0.16 worse than the analyst estimate of $1.18. Revenue for the quarter came in at $103.5 million versus the consensus estimate of $113.88 million.
AMAG Pharma sees FY2015 revenue of $425-450 million, versus prior guidance of $395-430 million and the consensus of $444.4 million.
For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Affle agrees to acquire Perion Network for ~$420 million
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
